Prospective Grant of Exclusive License: Development of Oncolytic Viral Cancer Therapies, 22333 [2012-8891]

Download as PDF Federal Register / Vol. 77, No. 72 / Friday, April 13, 2012 / Notices limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: April 9, 2012. Anna P. Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2012–8943 Filed 4–12–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of Oncolytic Viral Cancer Therapies National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents to Jennerex Biotherapeutics (‘‘Jennerex’’) located in San Francisco, CA, USA. Intellectual Property: 1. U.S. Patent No. 7,045,313 issued May 16, 2006 entitled, ‘‘Recombinant Vaccinia Virus Containing a Chimeric Gene Having Foreign DNA Flanked by Vaccinia Regulatory DNA’’ [HHS Ref. No. E–552–1982/2–US–03]; 2. U.S. Patent No. 7,015,024 issued March 21, 2006 entitled, ‘‘Compositions Containing Recombinant Poxviruses Having Foreign DNA Expressed under the Control of Poxvirus Regulatory Sequence’’ [HHS Ref. No. E–552–1982/ 2–US–04]; 3. U.S. Patent No. 7,045,136 issued May 16, 2006 entitled, ‘‘Methods of Immunization Using Recombinant Poxviruses Having Foreign DNA Expressed under the Control of Poxvirus Regulatory Sequence’’ [HHS Ref. No. E– 552–1982/2–US–05]; and 4. U.S. Patent No. 6,998,252 issued February 14, 2006 entitled, ‘‘Recombinant Poxviruses Having Foreign DNA Expressed under the Control of Poxvirus Regulatory Sequence’’ [HHS Ref. No. E–552–1982/ 2–US–06]. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be the U.S. and the field pmangrum on DSK3VPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 14:16 Apr 12, 2012 Jkt 226001 of use may be the ‘‘development and use of Licensed Patent Rights in combination with Licensee’s proprietary or in-licensed technologies for the treatment of human cancers’’. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 14, 2012 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Jennifer Wong, Senior Licensing and Patenting Manager, Cancer Branch, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4633; Facsimile: (301) 402– 0220; Email: wongje@mail.nih.gov. SUPPLEMENTARY INFORMATION: The instant technology relates to recombinant poxviruses, and in particular the vaccinia virus, as a backbone that carries a foreign DNA. The virus has been modified by inserting a chimeric gene containing foreign DNA adjacent to poxvirus transcriptional regulatory sequence. The recombinant virus is subsequently transfected into a host and the foreign gene is expressed. For example, the foreign DNA can be related to a viral pathogen, tumor-associated antigen, or therapeutic transgenes. Upon administration of the recombinant virus to a human or animal subject, the foreign gene is expressed in vivo to elicit an immune response or express the therapeutic genes. The technology takes advantage of the unique properties of poxviruses as a delivering vehicle and of the ease of preparation of such constructs. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 22333 Dated: April 10, 2012. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2012–8891 Filed 4–12–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY U.S. Citizenship and Immigration Services Agency Information Collection Activities: USCIS Case Status Online, Extension of a Currently Approved Information Collection; Comment Request 30-Day notice of information collection under review: USCIS case status online. ACTION: The Department of Homeland Security, U.S. Citizenship and Immigration Services (USCIS) is submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the Federal Register on January 30, 2012, at 77 FR 4574, allowing for a 60-day public comment period. USCIS did not receive any comments for this information collection. The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted until May 14, 2012. This process is conducted in accordance with 5 CFR 1320.10. Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Department of Homeland Security (DHS), and to the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), USCIS Desk Officer. Comments may be submitted to: Chief, Regulatory Coordination Division, Office of Policy and Strategy, USCIS, DHS, 20 Massachusetts Avenue NW., Suite 5012, Washington, DC 20529–2210. Comments may also be submitted to DHS via facsimile to 202–272–8352 or via email at USCISFRComment@dhs.gov, and to the OMB USCIS Desk Officer via facsimile at 202–395–6974 or via email at oira_submission@omb.eop.gov. E:\FR\FM\13APN1.SGM 13APN1

Agencies

[Federal Register Volume 77, Number 72 (Friday, April 13, 2012)]
[Notices]
[Page 22333]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-8891]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development of Oncolytic 
Viral Cancer Therapies

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR Part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in the 
following U.S. Patents to Jennerex Biotherapeutics (``Jennerex'') 
located in San Francisco, CA, USA.
    Intellectual Property:
    1. U.S. Patent No. 7,045,313 issued May 16, 2006 entitled, 
``Recombinant Vaccinia Virus Containing a Chimeric Gene Having Foreign 
DNA Flanked by Vaccinia Regulatory DNA'' [HHS Ref. No. E-552-1982/2-US-
03];
    2. U.S. Patent No. 7,015,024 issued March 21, 2006 entitled, 
``Compositions Containing Recombinant Poxviruses Having Foreign DNA 
Expressed under the Control of Poxvirus Regulatory Sequence'' [HHS Ref. 
No. E-552-1982/2-US-04];
    3. U.S. Patent No. 7,045,136 issued May 16, 2006 entitled, 
``Methods of Immunization Using Recombinant Poxviruses Having Foreign 
DNA Expressed under the Control of Poxvirus Regulatory Sequence'' [HHS 
Ref. No. E-552-1982/2-US-05]; and
    4. U.S. Patent No. 6,998,252 issued February 14, 2006 entitled, 
``Recombinant Poxviruses Having Foreign DNA Expressed under the Control 
of Poxvirus Regulatory Sequence'' [HHS Ref. No. E-552-1982/2-US-06].
    The patent rights in these inventions have been assigned to the 
United States of America.
    The prospective exclusive license territory may be the U.S. and the 
field of use may be the ``development and use of Licensed Patent Rights 
in combination with Licensee's proprietary or in-licensed technologies 
for the treatment of human cancers''.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before May 
14, 2012 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jennifer Wong, Senior Licensing and 
Patenting Manager, Cancer Branch, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Telephone: (301) 435-4633; Facsimile: (301) 
402-0220; Email: wongje@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The instant technology relates to 
recombinant poxviruses, and in particular the vaccinia virus, as a 
backbone that carries a foreign DNA. The virus has been modified by 
inserting a chimeric gene containing foreign DNA adjacent to poxvirus 
transcriptional regulatory sequence. The recombinant virus is 
subsequently transfected into a host and the foreign gene is expressed. 
For example, the foreign DNA can be related to a viral pathogen, tumor-
associated antigen, or therapeutic transgenes. Upon administration of 
the recombinant virus to a human or animal subject, the foreign gene is 
expressed in vivo to elicit an immune response or express the 
therapeutic genes. The technology takes advantage of the unique 
properties of poxviruses as a delivering vehicle and of the ease of 
preparation of such constructs.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
thirty (30) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR Part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 10, 2012.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2012-8891 Filed 4-12-12; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.